Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals

AIDS

Volumn 26, Issue 13, 2012, Pages 1707-1717

  Achhra, Amit C ^a   Amin, Janaki ^a   Sabin, Caroline ^b   Chu, Haitao ^c   Dunn, David ^d   Kuller, Lewis H ^e   Kovacs, Joseph A ^f   Cooper, David A ^a   Emery, Sean ^a   Law, Matthew G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

biomarker; cohort analysis; D dimer; HAART; HIV; net reclassification improvement; prognosis; risk assessment

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; D DIMER; INTERLEUKIN 2;

ADULT; ARTICLE; COHORT ANALYSIS; DEATH; EVALUATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT CODING; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; VALIDATION PROCESS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; HUMANS; MALE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84865522930     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328355d659     Document Type: Article

References (44)

1. Hoffmann CJ, Fielding KL, Johnston V, Charalambous S, Innes C, Moore RD, et al. Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr 2011; 58:269-276.
2. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005; 6:99-106. (Pubitemid 40425973)
3. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55:262-270.
4. Palella FJJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34. (Pubitemid 44306484)
5. Achhra AC, Amin J, Law MG, Emery S, Gerstoft J, Gordin FM, et al. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS 2010; 24:1877-1886.
6. Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, et al. CD4R count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841-848. (Pubitemid 351563833)
7. Friis-Møller N, Thiébaut R, Reiss P, Weber R, D'Arminio Monforte A, De Wit S, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study.Eur J Cardiovasc Prev Rehabil 2010; 17:491-501.
8. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi EM, et al. Low CD4R T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51:435-447.
9. Reekie J, Gatell JM, Yust I, Bakowska E, Rakhmanova A, Losso M, et al. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata. AIDS 2011; 25:2259-2268.
10. Justice AC, McGinnis KA, Skanderson M, Chang CC, Gibert CL, Goetz MB, et al. Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers. HIV Med 2010; 11:143-151.
11. Neaton JD, Neuhaus J, Emery S. Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. Curr Opin HIV AIDS 2010; 5:480-490.
12. Worm SW, Hsue P. Role of biomarkers in predicting CVD risk in the setting of HIV infection? Curr Opin HIV AIDS 2010; 5:467-472.
13. Baker J, Ayenew W, Quick H, Hullsiek KH, Tracy R, Henry K, et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis 2010; 201:285-292.
14. Neuhaus J, Jacobs J, David R, Baker Jason V, Calmy A, Duprez D, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.
15. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
16. Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 2010; 55:316-322.
17. Ioannidis JPA, Tzoulaki I. What makes a good predictor? The evidence applied to coronary artery calcium score. JAMA 2010; 303:1646-1647.
18. Grund B, Sabin C. Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves. Curr Opin HIV AIDS 2010; 5:473-479.
19. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MSV, et al. Criteria for evaluation of novel markers of cardiovascular risk. Circulation 2009; 119:2408-2416.
20. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115:928-935. (Pubitemid 46294733)
21. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem 2008; 54:17-23. (Pubitemid 351182592)
22. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009; 150:795-802.
23. Janes H, Pepe MS, Gu W. Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med 2008; 149:751-760.
24. Pencina MJ, D' Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27:157-172. (Pubitemid 351193639)
25. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engström G, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009; 302:49-57.
26. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008; 148:337-347. (Pubitemid 351665464)
27. Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008; 358:2107-2116. (Pubitemid 351679597)
28. Tzoulaki I, Liberopoulos G, Ioannidis JPA. Use of reclassification for assessment of improved prediction: an empirical evaluation.Int J Epidemiol 2011; 40:1094-1105.
29. Abrams D, Levy Y, Losso MH, Babiker A, Collins G, Cooper DA, et al.Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361:1548-1559.
30. Emery S, Abrams DI, Cooper DA, Darbyshire JH, Lane HC, Lundgren JD, et al. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials 2002; 23:198-220. (Pubitemid 34273853)
31. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296. (Pubitemid 44837777)
32. The SMART Study Group. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy. Ann Intern Med 2008; 149:289-299.
33. Sakkinen PA, Macy EM, Callas PW, Cornell ES, Hayes TE, Kuller LH, et al. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol 1999; 149: 261-267. (Pubitemid 29053167)
34. WHO. BMI Classification. http://apps.who.int/bmi/index.jsp? introPage¼intro-3.html [Accessed 1 December 2012].
35. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36. (Pubitemid 12142173)
36. Pencina MJ, D'Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30:11-21.
37. Chambless LE, Cummiskey CP, Cui G. Several methods to assess improvement in risk prediction models: extension to survival analysis. Stat Med 2011; 30:22-38.
38. Hileman CO, Carman TL, Gripshover BM, O'Riordan M, Storer NJ, Harrill DE, et al. Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIVinfected adults. AIDS 2010; 24:1958-1961.
39. Grinspoon SK. Statin therapy to improve atherosclerosis in HIV patients. Clinical trials. gov identifier: NCT00965185. http://clinicaltrials. gov/ct2/show/NCT00965185?term¼HIV +and + statins&rank¼ 1 [Accessed 1 December 2012].
40. AIDS Clinical Trials Group. Atorvastatin on biomarkers of inflammation, coagulopathy, angiogenesis and T-cells. Clinical Trials. gov identifier: NCT01351025. http://clinicaltrials. gov/ct2/show/NCT01351025?term¼HIV +and +statins&rank¼21 (Accessed 1 December 2012).
41. The Antiretroviral Therapy Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21:1185-1197.
42. Justice AC, Freiberg MS, Tracy R, Kuller L, Tate JP, Goetz MB, et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis 2012; 54:984-994.
43. Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, Telenti A, et al. Antiretroviral treatment of adult HIV infection. JAMA 2010; 304:321-333.
44. Mocroft A, Lifson AR, Touloumi G, Neuhaus J, Fox Z, Palfreeman A, et al. Haemoglobin and anaemia in the SMART study. Antivir Ther 2011; 16:329-337.